Literature DB >> 23100926

Cyclosporine A responsive pure red cell aplasia in a child with systemic lupus erythematosus.

Niranjan Biswal1, Parameswaran Narayanan, Ginigeri Chetan.   

Abstract

PRCA is a rare complication in SLE. Response to various drugs like steroid, Intravenous Immunoglobin (IVIG), recombinant human erythropoietin and plasmapheresis vary in different cases.Cyclosporin A may be effective in cases even unresponsive to other modalities of therapy.

Entities:  

Keywords:  Cyclosporine-A; PRCA; SLE

Year:  2008        PMID： 23100926      PMCID： PMC3453114          DOI： 10.1007/s12288-008-0008-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  5 in total

Review 1.  [Hematological abnormalities in patients with systemic lupus erythematosus].

Authors:  A García Tello; A Villegas Martínez; A F González Fernández
Journal:  An Med Interna       Date:  2002-10

2.  Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure.

Authors:  M Hinterberger-Fischer; P Höcker; K Lechner; H Seewann; W Hinterberger
Journal:  Eur J Haematol       Date:  1989-08       Impact factor: 2.997

3.  Human parvovirus B19 infection during the inactive stage of systemic lupus erythematosus.

Authors:  Takashiro Suzuki; Shinichiro Saito; Yasuhiko Hirabayashi; Hideo Harigae; Tomonori Ishii; Takao Kodera; Hiroshi Fujii; Yasuhiko Munakata; Takeshi Sasaki
Journal:  Intern Med       Date:  2003-06       Impact factor: 1.271

Review 4.  Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin.

Authors:  H Orbach; A Ben-Yehuda; D Ben-Yehuda; D Manor; A Rubinow; Y Naparstek
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

Review 5.  Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A.

Authors:  F Atzeni; P Sarzi-Puttini; F Capsoni; L Vulpio; M Carrabba
Journal:  Clin Exp Rheumatol       Date:  2003 Nov-Dec       Impact factor: 4.473
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.